Source comparison
Sermorelin Blood Work Labs: Before vs After Comparison
IGF-1 Age-adjusted reference. Typically 100–250 ng/mL depending on age 8–12 weeks, then every 3–6 months Increase of 30–60 ng/mL or into upper half of age-adjusted range Lack of increase signals non-response; excessive increase (>300 ng/mL) may require dose re
This comparison does not assign a generated winner or score.
- IGF-1
- Age-adjusted reference. Typically 100–250 ng/mL depending on age
- 8–12 weeks, then every 3–6 months
- Increase of 30–60 ng/mL or into upper half of age-adjusted range
- Lack of increase signals non-response; excessive increase (>300 ng/mL) may require dose reduction
- Fasting Glucose
- <100 mg/dL (optimal <90 mg/dL)
- 6–8 weeks if pre-diabetic at baseline; otherwise every 6 months
- Minimal change; slight increase (5–10 mg/dL) possible
- Rise above 100 mg/dL warrants metabolic workup; HbA1c recheck recommended
- HbA1c
- <5.7% (non-diabetic)
- Every 6 months
- No change expected in healthy individuals
- Increase of 0.3% or more signals worsening glycemic control. Consider discontinuation
- TSH
- 0.5–4.5 mIU/L (optimal 1.0–2.5 mIU/L)
- Every 6 months or if symptoms of hypo/hyperthyroidism develop
- Stable
- Rising TSH suggests developing hypothyroidism; recheck free T4 and T3
- Comprehensive Metabolic Panel
- Creatinine <1.2 mg/dL, ALT/AST within normal limits
- Annually unless baseline abnormalities present
- Elevated liver enzymes or creatinine require dose adjustment or discontinuation
- Lipid Panel (optional but recommended)
- LDL <130 mg/dL, HDL >40 mg/dL (men) or >50 mg/dL (women)
- Every 6–12 months
- Possible improvement in HDL and triglycerides
- GH has favourable effects on lipid metabolism; worsening lipids are atypical